Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 66,9369272184184-
Enterprise Value (EV)1 66,9369272184184184
P/E ratio -3,97x-17,5x-11,3x-7,24x-7,91x-9,82x
Yield ------
Capitalization / Revenue 558x4 113x1 715x390x46,1x15,5x
EV / Revenue 558x4 113x1 715x390x46,1x15,5x
EV / EBITDA --19,7x-11,3x-7,39x-6,97x-9,68x
Price to Book ------
Nbr of stocks (in thousands) 112 386162 740199 642216 248216 248-
Reference price (USD) 0,602,271,360,850,850,85
Announcement Date 04/01/201903/09/202003/29/2021---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 0,120,090,160,473,9911,9
EBITDA1 --18,7-24,0-24,9-26,4-19,0
Operating profit (EBIT)1 -14,6-18,9-24,2-24,8-24,5-16,5
Operating Margin -12 231%-21 068%-15 289%-5 243%-613%-139%
Pre-Tax Profit (EBT)1 -14,1-17,4-22,4-23,0-23,7-15,1
Net income1 -15,0-18,3-23,2-23,2-23,7-15,1
Net margin -12 516%-20 373%-14 678%-4 923%-593%-127%
EPS2 -0,15-0,13-0,12-0,12-0,11-0,09
Dividend per Share ------
Announcement Date 04/01/201903/09/202003/29/2021---
1 USD in Million
2 USD
Previous periodNext period
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 0,03--0,68--
EBITDA1 -6,29--6,82-7,10-7,00-6,60
Operating profit (EBIT)1 -6,35-4,79-6,88-6,74-7,10-6,60
Operating Margin -19 061%---999%--
Pre-Tax Profit (EBT)1 -4,96-4,79-6,84-6,46-5,90-
Net income1 -5,17-4,98-6,84-6,46-5,90-
Net margin -15 503%---957%--
EPS2 -0,03-0,02-0,03-0,03-0,03-0,04
Dividend per Share ------
Announcement Date 05/10/202108/10/202111/08/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt ------
Net Cash position ------
Leverage (Debt / EBITDA) ------
Free Cash Flow1 --14,5-17,4-25,1-28,0-27,4
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share ------
Cash Flow per Share ------
Capex 0,540,410,01---
Capex / Sales 448%452%3,63%---
Announcement Date 04/01/201903/09/202003/29/2021---
1 USD in Million
Previous periodNext period
Key data
Capitalization (USD) 183 983 396
Net sales (USD) 158 330
Number of employees 20
Sales / Employee (USD) 7 917
Free-Float 96,0%
Free-Float capitalization (USD) 176 620 890
Avg. Exchange 20 sessions (USD) 621 995
Average Daily Capital Traded 0,34%
EPS & Dividend